AstraZeneca Plc has acquired rights to an experimental drug for obesity in a significant expansion of its pipeline of cardiometabolic medicines. The agreement, with Eccogene Inc of China, was announced on 9 November concurrent with the release of the company’s third-quarter results. These showed a 5% increase in revenue to $11.5 billion. The revenue increase, which includes product sales, and collaboration and alliance revenue, was 6% at constant exchange rates. Excluding revenue from products developed for the Covid-19 pandemic, the revenue increase was a double-digit figure.
